IP Library Granted Patent US 6,893,657
Granted Patent B2
US 6,893,657 · App. 10/376,136 · Granted May 17, 2005

Solid dose delivery vehicle and methods of making same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,893,657
App. No.
10/376,136
Granted
May 17, 2005
Kind
B2
Abstract

The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.

Claims (7)

1. A therapeutic dried composition in solid dose form suitable for oral delivery, comprising a stabilizing polyol and immunogenic agent wherein the composition provides a quick release or flooding dose of the immunogenic agent after administration.

2. The composition, according to claim 1 , wherein the composition is freeze-dried.

3. The composition, according to claim 1 , wherein the immunogenic agent is selected from the group consisting of live and attenuated viruses, nucleotide vectors encoding antigens, bacteria and antigens.

4. The composition, according to claim 1 , wherein the immunogenic agent is an antigen selected from the group consisting of diptheria, tetanus, pertussis, botulinum, cholera, Dengue, hepatitis A, C and B, haemophilus influenzae b, herpes virus, Hylobacterium pylori , influenza, Japanese encephalitis, meningococci A, B and C, measles, mumps, papilloma virus, pneumococci, polio, rubella, rotavirus, respiratory syncytial virus, Shigella, tuberculosis, yellow fever and combinations thereof.

5. The composition, according to claim 1 , further comprising an amount of adjuvant effective to enhance an immune response to the immunogenic agent.

6. The composition, according to claim 5 , wherein the adjuvant is selected from the group consisting of aluminium salts, squalene mixtures (SAF-1), muramyl peptide, saponin derivatives, mycobacterium cell wall preparations, monophosphoryl lipid A, mycolic acid derivtives, nonionic block copolymer surfacants, Quil A, cholera toxin B subunit, polyphosphazene, immunostimulating complexes and mitogenic components of Freund's adjuvant.

7. The composition, according to claim 1 , wherein the stabilizing polyol is selected from the group consisting of monosaccharides, disaccharides, trisaccharides, oligosaccharides.

Assignments (2)
CHANGE OF NAME Recorded Aug 27, 2003
From: ELAN DRUG DELIVERY LTD.
To: QUADRANT DRUG DELIVERY LIMITED
Reel/Frame 013918/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2003
From: QUADRANT HEALTHCARE (UK) LIMITED
To: ELAN DRUG DELIVERY LTD.
Reel/Frame 013695/0198 →